Antonello Michele, Squizzato Francesco, Colacchio Elda Chiara, Spertino Andrea, Grego Franco, Piazza Michele
Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Vascular and Endovascular Surgery Clinic, Padova University, School of Medicine, Padova, Italy.
Surg Technol Int. 2022 Jan 11;40. doi: 10.52198/22.STI.40.CV1509.
To describe our experience with the Gore® C-TAG® endograft with ACTIVE CONTROL System (ACS) (W.L. Gore & Associates, Inc., Flagstaff, AZ, USA) in thoracic aortic repair, focusing on deployment accuracy and aortic wall apposition.
All patients who underwent thoracic endovascular aortic repair (TEVAR) using the Gore® C-TAG® endograft with ACS from September 2017 to September 2021 were enrolled in a dedicated database and retrospectively analysed. We collected anatomic data on aortic arch angulation and tortuosity, proximal and distal landing zones, and the target for deployment accuracy. Proximal and distal deployment accuracies (PDA and DDA) were measured through intraoperative digital subtraction angiography (DSA), and postoperative computed tomography angiography (CTA) was required to define endograft apposition to the aortic wall.
Twenty-eight patients who underwent TEVAR with the Gore® C-TAG® with ACS at our institution were selected for this study: 46% presented with a type 3 aortic arch and a proximal landing zone < 3 was used in 53% of cases. Mean PDA and DDA were 1.89 ± 3.5 mm and 0.6 ± 1.4 mm, and were obtained in 93% and 100% of procedures, respectively. Mean proximal and distal wall apposition were 91 ± 17% and 98 ± 5.9%. Fifteen patients required an associated planned procedure, either to revascularize supra-aortic vessels when PLZ was < 3 or to assure optimal distal fixation with EndoAnchors™ (Medtronic, Minneapolis, MN, USA) delivery in selected cases. Two patients required reintervention during the same hospitalisation because of type 1a endoleak onset. No further reinterventions were needed during follow-up.
Our single-centre analysis found promising results using the Gore® C-TAG® with ACS, with an optimal accuracy in deployment and wall apposition at both proximal and distal landing zones.
描述我们使用带有主动控制系统(ACS)的戈尔®C-TAG®血管内移植物(美国亚利桑那州弗拉格斯塔夫市W.L.戈尔联合公司)进行胸主动脉修复的经验,重点关注释放准确性和主动脉壁贴合情况。
将2017年9月至2021年9月期间使用带有ACS的戈尔®C-TAG®血管内移植物进行胸主动脉腔内修复(TEVAR)的所有患者纳入一个专门数据库,并进行回顾性分析。我们收集了主动脉弓角度和迂曲度、近端和远端锚定区以及释放准确性目标的解剖学数据。通过术中数字减影血管造影(DSA)测量近端和远端释放准确性(PDA和DDA),并需要术后计算机断层扫描血管造影(CTA)来确定血管内移植物与主动脉壁的贴合情况。
本研究选取了在我们机构接受使用带有ACS的戈尔®C-TAG®进行TEVAR的28例患者:46%呈现3型主动脉弓,53%的病例使用的近端锚定区<3cm。平均PDA和DDA分别为1.89±3.5mm和0.6±1.4mm,分别在93%和100%的手术中获得。近端和远端壁贴合的平均值分别为91±17%和98±5.9%。15例患者需要进行相关的计划性手术,当近端锚定区<3cm时,为主动脉弓上血管进行血运重建,或在特定病例中使用EndoAnchors™(美国明尼苏达州明尼阿波利斯市美敦力公司)确保最佳远端固定。2例患者在同一住院期间因1a型内漏发生需要再次干预。随访期间无需进一步再次干预。
我们的单中心分析发现,使用带有ACS的戈尔®C-TAG®取得了令人鼓舞的结果,在近端和远端锚定区的释放和壁贴合方面具有最佳准确性。